Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aytu BioPharma, Inc. - Common Stock (NQ:AYTU)

2.390 +0.070 (+3.02%)
Streaming Delayed Price Updated: 1:43 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
Via ACCESS Newswire
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
Via ACCESS Newswire
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
Via ACCESS Newswire
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
Via ACCESS Newswire
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
Via ACCESS Newswire
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Via ACCESS Newswire
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
Via ACCESSWIRE
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
Via ACCESS Newswire
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
Via ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
Via ACCESS Newswire
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Via ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
Via ACCESS Newswire
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
Via ACCESSWIRE
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Via ACCESSWIRE
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Via ACCESSWIRE
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Via ACCESSWIRE
Aytu BioPharma Disclosure Notification
Via ACCESSWIRE
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
Via ACCESSWIRE
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
Via ACCESSWIRE
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
Via ACCESSWIRE
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Via ACCESSWIRE
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
Via ACCESSWIRE
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
Via ACCESSWIRE
Sidoti Events, LLC's Virtual August Micro-Cap Conference
Via ACCESSWIRE
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
Via ACCESSWIRE
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and... 
Via Newsfile
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Via ACCESSWIRE
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Via ACCESSWIRE
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.